J Ethnopharmacol:连翘水提取物减轻了四氯化碳(CCl4)诱导的小鼠肝纤维化程度

2018-03-17 MedSci MedSci原创

连翘水提取物通过抑制肝星状细胞(HSCs)激活,减少肝细胞外基质(ECM)的增加,逆转上皮间质转化(EMT),来减弱ccl4诱导的小鼠肝纤维化程度

研究背景:连翘的果实(Thunb)Vahl是一种著名的中药(中药),用于清除热量、有毒物质和肿块。本研究的目的是在雄性C57BL/6小鼠中,观察连翘水提取物对四氯化碳(CCl4)所致的肝纤维化的影响。

研究方法:在雄性C57BL/6小鼠中,通过腹腔注射2ml/kg CCl4(混合1:3),每周2次,连续4周来制作小鼠肝纤维化模型。与此同时,小鼠在4周内每天口服连翘水提取物(1, 2g/kg)。分析与肝纤维化有关的血清生化参数、基因和蛋白表达。

研究结果:血清丙氨酸/天冬氨酸转氨酶(ALT/AST)活性和肝脏组织学评价均显示出连翘水提取物对CCl4诱导的肝损伤有保护作用。此外,马森三色和天狼星红染色、肝羟脯氨酸含量、透明质酸、层蛋白、胶原和三型前胶原蛋白(PCIII)的结果也证明了连翘水提取物的抗纤维化效应。连翘水提取物也减轻了肝纤维化小鼠肝脏中a-平滑肌肌动蛋白的表达。此外,连翘水提取物降低了CCl4诱导的小鼠纤维母细胞特异性蛋白1 (FSP1)和波形蛋白在肝脏的表达。

研究结论:连翘水提取物通过抑制肝星状细胞(HSCs)激活,减少肝细胞外基质(ECM)的增加,逆转上皮间质转化(EMT),来减弱ccl4诱导的小鼠肝纤维化程度。

原始出处

Zhang Y, Miao H, Yan H, et al. Hepatoprotective effect of Forsythiae Fructuse water extract against carbon tetrachloride-induced liver fibrosis in mice. J Ethnopharmacol, 2018, Feb 20;218:27-34. doi: 10.1016/j.jep.2018.02.033.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-12-10 yb6560
  2. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2019-01-02 jj000001
  4. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1996149, encodeId=f36e199614944, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Mon Dec 10 08:52:00 CST 2018, time=2018-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788300, encodeId=03341e8830085, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Aug 14 10:52:00 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787454, encodeId=3cb81e874549d, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Wed Jan 02 07:52:00 CST 2019, time=2019-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1808196, encodeId=09171808196d6, content=<a href='/topic/show?id=f94d81342e5' target=_blank style='color:#2F92EE;'>#肝纤维#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81342, encryptionId=f94d81342e5, topicName=肝纤维)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Tue Mar 20 08:52:00 CST 2018, time=2018-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908410, encodeId=185a19084105e, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Mar 31 06:52:00 CST 2018, time=2018-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490671, encodeId=5fba14906e131, content=<a href='/topic/show?id=c5cb421596' target=_blank style='color:#2F92EE;'>#CCl4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4215, encryptionId=c5cb421596, topicName=CCl4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95d48802713, createdName=liuhuangbo, createdTime=Mon Mar 19 11:52:00 CST 2018, time=2018-03-19, status=1, ipAttribution=)]
    2018-03-19 liuhuangbo

相关资讯

J Cell Biochem:乳腺癌EMT调节的关键轴——GRHL2 / ZEB反馈环

超过90%的癌症相关死亡是由转移引起的。其中,上皮-间质转化(EMT)引起肿瘤细胞的传播并且是可逆过程,间质-上皮转化(MET)允许癌细胞生长并建立潜在的致死转移性病变。最近的研究证据表明,除了E和M,细胞可以采取稳定的混合上皮/间质(E / M)状态,它们可以集体移动导致循环肿瘤细胞的簇集-转移的“坏行动者”。近期,一项发表在杂志J Cell Biochem上的研究假设EMT发生在乳腺癌所有四种

Nat Mater:癌转移的两种行军方式

为了研究肿瘤细胞的侵袭机制,科学家们设计了一个微小的设备,将其作为细胞们的障碍赛场地。在上皮-间充质细胞转化(EMT)过程中,组织中彼此粘附的上皮细胞,会转变成为可以具有较强迁移能力的间充质细胞。在胚胎发育中EMT是一个有益的过程,细胞通过EMT在胚胎中移动并建立特化的组织。不过近年来人们发现,EMT也在癌转移中起到了关键性的作用。研究人员通过特殊的微观设备模拟肿瘤周围的组织,并让正在经历EMT的

Cancer Res:SOX4调节EMT促进乳腺癌发展

7月11日,Cancer Res杂志在线报道了SOX4通过调节上皮-间质转化(EMT)过程而促进乳腺癌发展,并可作为一项判断预后的新的生物标记。 上皮 - 间质转化(EMT)是一个与乳腺癌的发展和转移有关的发育过程。本研究发现,异位过表达SOX4足以使永生化人类乳腺上皮细胞获得间质组织性状,从而增强细胞迁移和侵袭。此外,这些细胞还获得了上皮干细胞的属性,表现为具有CD44增高/CD24降低特征的

IJC:上皮间质转化与肿瘤转移

大量研究证实上皮-间质转化(EMT)是与癌症的侵袭和转移有牵连的关键事件。肿瘤细胞经过血液循环传播后,肿瘤细胞会发生间质上皮转化(MET),形成继发性的肿瘤转移灶。 然而,肿瘤细胞的这种形态学上的变化并没有从人类肿瘤标本组织中得到很有力的证据。在上皮癌组织中,上皮型细胞形态和基因表达在一定程度上得到了保留。虽然转化成间质型肿瘤细胞可能涉及许多癌症类型包括肉瘤,但在某些肿瘤中,分化成间质型的肿瘤细

JBC:肝细胞核因子-6(HNF6)诱导EMT促进肺癌浸润转移

国际学术期刊Journal of Biological Chemistry 近日在线发表了生化与细胞所宋建国研究组题为“Hepatocyte Nuclear Factor 6 suppresses the migration and invasive growth of lung cancer cells through p53 and the inhibitio

Stem cells:在成釉细胞瘤上皮细胞中,间充质干细胞分泌的IL-6促进上皮细胞-间质细胞转化和上皮干细胞样细胞特性的获得。

上皮细胞-间质细胞转化(EMT),是一种与癌症干细胞样细胞或癌症原始细胞形成相关的生理过程,对恶性肿瘤的侵袭性、转移、耐药性和复发均有一定的促进作用。成釉细胞瘤(AM),是一种良性但局限性侵袭性生长的牙源性肿瘤,目前,尚不知道EMT是否在AM的病理过程中发挥作用。本文中研究人员证明EMT和干细胞相关基因在最常见的组织变异亚型的上皮组织孤岛(滤泡AM)中表达,还发现在滤泡AM的基质腔中,IL-6信号